The most straightforward structural trade in healthcare investing has been hiding in plain sight for a decade: the same procedure, performed by the same physician, at an ambulatory surgery center costs payers between thirty and sixty percent less than at a hospital outpatient department.
CMS has documented this differential extensively and has been adjusting payment policy accordingly—the site-neutral payment initiative has gradually expanded the list of procedures for which Medicare pays the same regardless of setting. Commercial payers have been moving in the same direction, with varying speed depending on their market leverage relative to hospital systems that control physician referral patterns.
MedPricer.org makes this differential legible at the commercial market level and at the procedure level. By querying negotiated rates for high-volume elective procedures—cataract surgery, knee arthroscopy, colonoscopy, hernia repair—across hospital outpatient departments and freestanding ASCs in the same metropolitan area, an analyst can quantify the price gap that payers face and that drives their interest in steering volume to lower-cost settings.
The investment thesis follows directly. ASC operators—both publicly traded entities and the platforms backed by private equity—are positioned to capture volume migrating from hospital outpatient departments as payers redesign benefit structures to incentivize lower-cost site selection. Publicly traded operators like United Surgical Partners International (a Tenet subsidiary), Surgery Partners, and SurgCenter Development platforms receive payer contract pricing that is, in most markets, substantially lower than hospital outpatient rates for the same procedures.
MedPricer’s market-level analysis allows a fund to identify which geographies have the largest hospital-to-ASC rate differentials—and thus the strongest payer incentive to shift volume. A market where commercial payers are paying hospital outpatient departments 250% of Medicare for colonoscopies while paying ASCs 130% of Medicare has a documented $200 billion addressable market in ASC site-of-care shifting. A market where the differential is 20% has a much weaker payer incentive and correspondingly slower volume migration dynamics.
The counterforce to this thesis is hospital system resistance. Large hospital systems earn substantial margins on outpatient procedures and have responded to ASC competition through several strategies: acquiring or joint-venturing with ASC operators to capture the volume within their own networks, using payer contract negotiations to resist benefit design changes that would steer to freestanding ASCs, and using physician employment to control referral patterns. The success of these countermeasures varies by market, and MedPricer data—which shows whether ASC rates in a given market are converging toward hospital outpatient rates (a sign of hospital counter-leverage) or diverging—provides a leading indicator.
The geographic screen for this strategy prioritizes markets where hospital market concentration is moderate rather than high. In highly concentrated hospital markets, systems have sufficient leverage to resist payer-driven site-of-care shifting and to acquire or partner with ASC competitors. In moderately concentrated markets, payer leverage is more balanced, and the ASC price advantage is more likely to translate into genuine volume migration.
Surgery Partners (SGRY) and similar publicly traded ASC operators are natural vehicles for this thesis, but their operating leverage cuts in both directions. Volume concentration in elective procedures makes their revenue highly sensitive to utilization trends—catastrophically demonstrated during the COVID-19 procedure shutdown. The long-term structural case is strong; the quarterly volatility is real. Rate data from MedPricer can help a fund assess whether a given quarter’s volume miss reflects a durable competitive headwind or a temporary utilization disruption.
